A phase I study of SPI-077 (Stealth® liposomal cisplatin) concurrent with radiation therapy for locally advanced head and neck cancer

David I. Rosenthal, Sue S. Yom, Li Liu, Mitchell Machtay, Kenneth Algazy, Randal S. Weber, Gregory S. Weinstein, Ara A. Chalian, Linda K. Miller, Kenneth Rockwell, Margaret Tonda, Edward Schnipper, Diane Hershock

Research output: Contribution to journalArticle

35 Scopus citations

Abstract

Background: Liposomal cisplatin preparations have two potential advantages over the free drug when combined with radiation therapy (RT): 1) selective tumor localization, improving the therapeutic ratio, and 2) prolonged half-life, allowing more radiosensitization. We performed a Phase I study of Stealth® liposomal cisplatin (SPI-077) concurrent with RT for head and neck squamous cell carcinoma (HNSCC). Methods: Patients with Stage IVa/b HNSCC were treated with SPI-077, given intravenously twice two weeks apart, concurrent with RT (60-72 Gy in 6-7 weeks). The SPI-077 dose was escalated in standard phase I design. Results: Twenty patients received 38 doses of SPI-077, escalated from 20-200 mg/m2 in six dose levels. Two of these patients received one dose because of reversible Grade 3 liver toxicity or rash. Three patients had a Grade 1, and one had a Grade 2 infusion reaction. Four patients had transiently elevated transaminases: Grade 1 (n = 1), Grade 2 (n = 1), and Grade 3 (n = 2). Grade 3 neutropenia occurred in one patient. There was no ototoxicity, neurotoxicity, or nephrotoxicity. In-field radiation skin and mucosal toxicities did not appear to be intensified. Ten of 17 patients (59%) finishing treatment achieved initial complete response. Conclusions: Systemic and in-field radiation toxicities of SPI-077 were minimal. Infusion reactions were minimized with a slower and more dilute initial infusion. Further dose escalation was stopped in the absence of dose-limiting toxicity to address the reformulation of the liposomally bound cisplatin. Nonetheless, this study shows that high doses of SPI-077 can be given safely. The potentially beneficial therapeutic ratio suggests that liposomal radiosensitizer preparations warrant further investigation.

Original languageEnglish (US)
Pages (from-to)343-349
Number of pages7
JournalInvestigational New Drugs
Volume20
Issue number3
DOIs
StatePublished - Aug 8 2002

All Science Journal Classification (ASJC) codes

  • Oncology
  • Pharmacology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'A phase I study of SPI-077 (Stealth® liposomal cisplatin) concurrent with radiation therapy for locally advanced head and neck cancer'. Together they form a unique fingerprint.

  • Cite this

    Rosenthal, D. I., Yom, S. S., Liu, L., Machtay, M., Algazy, K., Weber, R. S., Weinstein, G. S., Chalian, A. A., Miller, L. K., Rockwell, K., Tonda, M., Schnipper, E., & Hershock, D. (2002). A phase I study of SPI-077 (Stealth® liposomal cisplatin) concurrent with radiation therapy for locally advanced head and neck cancer. Investigational New Drugs, 20(3), 343-349. https://doi.org/10.1023/A:1016201732368